Burden of Illness
Health-Related Quality of Life
Healthcare Resource Utilization
Patient Reported Outcomes
Real-world data sources have historically provided limited access to information about the occurrence of disease progression. As a result, progression-free survival (PFS), a standard effectiveness...
Real‐world data are lacking in assessing the real world effectiveness of fulvestrant monotherapy for use in post-menopausal women with hormone receptor-positive, metastatic breast cancer (MBC) who...
Anecdotal and early evidence suggest ICIs are being used in patients with advanced malignancies and history of AD, despite such patients being typically excluded from traditional clinical trials. We...
Restrictive trial eligibility criteria limit data generalizability and patient opportunity to participate. This study compared numbers and characteristics of patients eligible using traditional vs...
This study sought to describe the characteristics of patients with aNSCLC receiving ICIs in the real-world, as well as to examine treatment patterns and outcomes in the time since initial ICI...
Although patients with AD are routinely excluded from ICI clinical trials, evidence suggests they may be receiving ICI therapy once approved. This study sought to understand the prevalence of AD...